Home・Aktien・Glaukos Corp
Search

Glaukos Corp

Geschlossen

BrancheGesundheitswesen

184.3 -2.71

Starkes Kaufsignal

Kursupdate 14. Aug. 2026, 19:59 UTC

BuySell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

183.83

Max

189.31

Schlüsselkennzahlen

By Trading Economics

Einkommen

1.4M

-18M

Verkäufe

35M

186M

EPS

-0.14

Gewinnspanne

-9.901

Angestellte

1,094

EBITDA

-11M

-16M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+0.17% upside

Dividenden

By Acuity

Nächstes Ergebnis

28. Okt. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.8B

11B

Vorheriger Eröffnungskurs

187.01

Vorheriger Schlusskurs

184.3

Nachrichtenstimmung

By Acuity

50%

50%

163 / 340 Ranking in Healthcare

Glaukos Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Aug. 2026, 19:46 UTC

Glaukos Corp. shares are lower today, reaching a session low amid broader market declines following a surprise drop in U.S. retail sales for July.

Lesen

13. Aug. 2026, 19:22 UTC

Glaukos Corp. shares are higher today amid unusually high trading volume. The stock remains significantly above its 20-day moving average.

Lesen

12. Aug. 2026, 19:16 UTC

Glaukos Corp shares are higher today, supported by overall strength in U.S. stocks and positive quarterly results from AI sector companies.

Lesen

10. Aug. 2026, 20:06 UTC

Glaukos Corp shares are higher today, following a broader market trend since Friday. Earlier, the stock reached a session high before pulling back.

Lesen

7. Aug. 2026, 20:02 UTC

Glaukos Corp shares are rising in Friday's session, supported by unusually high trading volume and a steady upward trend since Thursday's close.

Lesen

4. Aug. 2026, 19:36 UTC

Glaukos Corp shares are lower today, impacted by declines in the Health Care Equipment sub-sector. The stock pulled back after reaching an earlier high.

Lesen

3. Aug. 2026, 20:06 UTC

Glaukos Corp shares are higher amid positive market sentiment, with the S&P 500 and Nasdaq 100 also gaining. The stock remains above its 20-day moving average.

Lesen

31. Juli 2026, 19:45 UTC

News

Glaukos shares are lower today despite H.C. Wainwright raising the price target to $195 from $168. Trading volume has been unusually high.

Lesen

30. Juli 2026, 21:31 UTC

News

Glaukos Corp shares are lower in after-market trading, tracking declines in the Health Care Equipment sector. UBS raised its price target to $172.

Lesen

29. Juli 2026, 21:22 UTC

Social Media
News

Glaukos Corp reported record net sales of $185.6 million in Q2 2026, raising its full-year revenue guidance to $680 million to $700 million. Shares are higher in after-market trading.

Lesen

28. Juli 2026, 17:46 UTC

News

Glaukos Corp shares are lower after UBS initiated coverage with a Neutral rating, overshadowing Stifel's Buy rating and $175 price target.

Lesen

27. Juli 2026, 19:16 UTC

Glaukos Corp shares are lower today, despite an initial gain. Broader market trends are affected by a significant drop in oil prices.

Lesen

24. Juli 2026, 19:56 UTC

Glaukos Corp. shares are trading higher today, maintaining a cumulative gain since Thursday and remaining above their 20-day moving average.

Lesen

21. Juli 2026, 17:41 UTC

Glaukos Corp shares are lower today amid a decline in the Health Care Equipment sub-sector, reversing the recent trend of higher daily closes.

Lesen

Peer-Vergleich

Kursveränderung

Glaukos Corp Prognose

Kursziel

By TipRanks

0.17% Vorteil

12-Monats-Prognose

Durchschnitt 189.77 USD  0.17%

Hoch 225 USD

Tief 153 USD

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Glaukos Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

14 ratings

13

Buy

1

Halten

0

Sell

Basierend auf 14 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Glaukos Corp – Dist abgegeben haben.

Stimmung

By Acuity

163 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Andere Aktien aus dem Sektor

LLY

Eli Lilly and Co.

1,181.06

↓-2.09%

JNJ

Johnson and Johnson

260.24

↓-0.76%

ABBV

AbbVie Inc

249.29

↓-0.63%

UNH

UnitedHealth Group Inc

401.62

↑ +0.62%

MRK

Merck & Co Inc.

135.76

↑ +0.27%
help-icon Live chat